These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19018980)

  • 1. Features and consequences of untreated type 1 autoimmune hepatitis.
    Czaja AJ
    Liver Int; 2009 Jul; 29(6):816-23. PubMed ID: 19018980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.
    Ichai P; Duclos-Vallée JC; Guettier C; Hamida SB; Antonini T; Delvart V; Saliba F; Azoulay D; Castaing D; Samuel D
    Liver Transpl; 2007 Jul; 13(7):996-1003. PubMed ID: 17370335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    J Clin Gastroenterol; 2008 Oct; 42(9):1047-53. PubMed ID: 18719506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.
    Czaja AJ; Carpenter HA
    J Hepatol; 2004 Apr; 40(4):646-52. PubMed ID: 15030981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4.
    Czaja AJ; Carpenter HA; Moore SB
    Liver Int; 2006 Jun; 26(5):552-8. PubMed ID: 16761999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of treatment withdrawal in type 1 autoimmune hepatitis.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Liver Int; 2007 May; 27(4):507-15. PubMed ID: 17403191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Am J Gastroenterol; 2007 May; 102(5):1005-12. PubMed ID: 17319926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and nature of the variant syndromes of autoimmune liver disease.
    Czaja AJ
    Hepatology; 1998 Aug; 28(2):360-5. PubMed ID: 9695997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients.
    Granito A; Muratori L; Pappas G; Muratori P; Ferri S; Cassani F; Lenzi M; Bianchi FB
    Aliment Pharmacol Ther; 2005 May; 21(10):1273-7. PubMed ID: 15882249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Hepatology; 2007 Oct; 46(4):1138-45. PubMed ID: 17668882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.
    Czaja AJ; Menon KV; Carpenter HA
    Hepatology; 2002 Apr; 35(4):890-7. PubMed ID: 11915036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis.
    Czaja AJ; Carpenter HA
    Hepatology; 2004 Jun; 39(6):1631-8. PubMed ID: 15185304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis.
    Czaja AJ
    J Hepatol; 2009 Jul; 51(1):161-7. PubMed ID: 19446908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis.
    Rebollo Bernárdez J; Cifuentes Mimoso C; Piñar Moreno A; Caunedo Alvarez A; Salas Herrero E; Jiménez-Sáenz M; Herrerías Gutiérrez J
    Rev Esp Enferm Dig; 1999 Sep; 91(9):630-8. PubMed ID: 10502711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of Japanese male patients with type 1 autoimmune hepatitis.
    Miyake Y; Iwasaki Y; Sakaguchi K; Shiratori Y
    Aliment Pharmacol Ther; 2006 Aug; 24(3):519-23. PubMed ID: 16886918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases.
    Miyake Y; Iwasaki Y; Terada R; Onishi T; Okamoto R; Sakai N; Sakaguchi K; Shiratori Y
    Aliment Pharmacol Ther; 2006 May; 23(9):1347-53. PubMed ID: 16629940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune liver disease associated with celiac disease in childhood: a multicenter study.
    Caprai S; Vajro P; Ventura A; Sciveres M; Maggiore G;
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):803-6. PubMed ID: 18258488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study.
    Floreani A; Niro G; Rosa Rizzotto E; Antoniazzi S; Ferrara F; Carderi I; Baldo V; Premoli A; Olivero F; Morello E; Durazzo M
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1051-7. PubMed ID: 16984499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis.
    Mehendiratta V; Mitroo P; Bombonati A; Navarro VJ; Rossi S; Rubin R; Herrine SK
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):98-103. PubMed ID: 18955163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis.
    Abe M; Onji M; Kawai-Ninomiya K; Michitaka K; Matsuura B; Hiasa Y; Horiike N
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):255-8. PubMed ID: 17218164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.